MERS CoV News and Research

RSS

In recent history, we have witnessed the emergence of several different life-threatening viruses. In addition to causing serious public health concerns around the globe, they have been responsible for significant human morbidity and mortality. Modern life that entails uncurtailed travel of humans and goods means that initially localized outbreaks may pose a risk of transmission anywhere in the world.

COVID-19 pandemic and nanotechnology

Writing in the International Journal of Nanomedicine, Professor Dongki Yang, from the Department of Physiology, Gachon University, South Korea, has reviewed the available knowledge on the coronaviruses, current approaches to tackle the newly emerged SARS-CoV-2 infection, and the innovative application of nanotechnology in the COVID-19 pandemic.

8 Feb 2021

SARS-CoV-2 delays interferon signaling in host cells

A team of scientists from Sweden and India has recently conducted a study to evaluate type I interferon (IFN-I) responses in cells infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The findings reveal that SARS-CoV-2 infection is associated with a delayed and dysregulated IFN-I response and that pretreatment with IFN-I can reduce the risk of SARS-CoV-2 infection.

7 Feb 2021

Monoclonal antibodies against SARS-CoV-2 spike's N-terminal prove highly protective in vivo

A new study server reports highly protective neutralizing monoclonal antibodies against the SARS-CoV-2.

4 Feb 2021

One dose of VSV-vectored vaccine prevents SARS-CoV-2 replication in hamsters

A new preprint research paper posted to the bioRxiv server describes a viral vector vaccine candidate's efficacy to protect against SARS-CoV-2 replication in a hamster model.

3 Feb 2021

Highly conserved neutralizing epitope identified on SARS-CoV-2 spike protein

A recent study conducted at the University of Texas at Austin, USA, has identified a highly conserved neutralizing antibody binding site on the spike S2 domain of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The study findings might help develop novel spike-targeting antibodies for widespread protection. The study is currently available on the bioRxiv preprint server.

2 Feb 2021

Researchers explore adaptive immunity against human coronaviruses

A recent study shows that long-term adaptive immunity to endemic coronaviruses is widespread, but low in magnitude, and that it shares phenotypic features of spike-specific antibodies and T cell memory across all tested coronaviruses.

29 Jan 2021

Viral ExoN regulates the rate of recombination in SARS-CoV-2

Researchers at Vanderbilt University Medical Center (VUMC) and the University of Texas Medical Branch (UTMB) at Galveston have discovered what may be the Achilles' heel of the coronavirus, a finding that may help close the door on COVID-19 and possibly head off future pandemics.

28 Jan 2021

SARS-CoV-2 spike may impair antigen presentation by CD8 T cells

A new study published on the bioRxiv preprint server aims to identify specific viral epitopes on the spike protein from various regions of the spike protein and the T cell responses they evoke.

27 Jan 2021

Study looks at anxiety of HCW during the COVID-19 pandemic

The study reveals that healthcare workers from Saudi Arabia suffer from a high level of anxiety due to a higher risk of acquiring severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. The study is currently available on the medRxiv* preprint server.

24 Jan 2021

SARS-CoV-2’s nonstructural proteins dysregulate immune responses, study finds

Researchers provide an overview of SARS-CoV-2 and its life cycle pathways, addressing the functional changes in the viral proteins, providing important strategic clues to help that may help in the ongoing development of therapies against COVID-19.

22 Jan 2021

Does hypertension always lead to severe COVID-19?

Researchers have developed some prognostic factors to predict the severity of COVID-19 among hypertensive patients.

22 Jan 2021

Immune systems of COVID-19 patients may rely on antibodies from earlier coronaviruses

The results of a study led by Northern Arizona University and the Translational Genomics Research Institute (TGen), an affiliate of City of Hope, suggest the immune systems of people infected with COVID-19 may rely on antibodies created during infections from earlier coronaviruses to help fight the disease.

20 Jan 2021

Mapping antibody reactivity in COVID-19 patients by using multi-coronavirus protein microarray

In an exciting, state-of-the-art study currently available on the medRxiv* preprint server, US researchers created a multi-coronavirus protein microarray containing full-length proteins, peptide libraries, and overlapping protein fragments from the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), as well as four other human coronaviruses.

19 Jan 2021

A snake venom enzyme shows anti-SARS-CoV-2 activity in vitro

A new study reports the virucidal and fusion-inhibiting attributes of snake venom against the COVID-19 agent SARS-CoV-2.

14 Jan 2021

MVA SARS-CoV-2 vaccine candidate shows strong immunogenicity in preclinical trials

A new study reports the preclinical testing of a recombinant MVA (rMVA) candidate vaccine against SARS-CoV-2, the agent that is causing the current COVID-19 pandemic.

14 Jan 2021

Researchers map genetic changes that may have facilitated SARS-CoV-2’s jump from bats to humans

Researchers from the University of Cambridge and the Pirbright Institute in the UK have identified key genetic changes in SARS-CoV-2 that may be responsible for the virus’s jump from bats to humans. The team also determined which animals contain cellular receptors that allow the virus to enter cells more effectively, zoning in on potential animals that acted as an intermediary host in facilitating SARS-CoV-2’s zoonosis.

13 Jan 2021

SARS-CoV-2 may join the ranks of mild cold-causing coronaviruses

What is the endgame for SARS-CoV-2, the virus that is causing worldwide devastation? If it becomes endemic -- circulating in the general population -- and most people are exposed in childhood, SARS-CoV-2 may join the ranks of mild cold-causing coronaviruses that currently circulate in humans, according to a model developed by Emory and Penn State scientists.

13 Jan 2021

Study supports continuing phase 3 trials of Ad26.COV2.S SARS-CoV-2 vaccine

An international team of researchers has provided further evidence to confirm the immunogenicity and efficacy of a recombinant adenovirus vaccine currently being tested in phase 3 trials for its ability to protect against infection with severe acute respiratory coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).

11 Jan 2021

SARS-CoV-2-induced innate immune responses may vary with disease severity, finds study

Scientists from Germany and China recently conducted a large meta-analysis using transcriptome data of SARS-CoV-2 to evaluate the routes of viral entry and the characteristics of innate immune responses induced by SARS-CoV-2 infection.

11 Jan 2021

Large-scale genome sequencing shows how SARS-CoV-2 mutated

A new study published on the preprint server bioRxiv* describes the results of genomic sequencing of the virus, which may help trace the routes of transmission of the virus from person to person, and from country to country.

10 Jan 2021